Does FDG-PET/CT for incidentally found pulmonary lesions lead to a cascade of more incidental findings?

Fluorodeoxyglucose F18 Health care costs Incidental findings Positron emission tomography computed tomography Solitary pulmonary nodule

Journal

Clinical imaging
ISSN: 1873-4499
Titre abrégé: Clin Imaging
Pays: United States
ID NLM: 8911831

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 13 12 2023
revised: 13 02 2024
accepted: 28 02 2024
medline: 18 3 2024
pubmed: 10 3 2024
entrez: 9 3 2024
Statut: ppublish

Résumé

To determine the frequency, nature, and downstream healthcare costs of new incidental findings that are found on whole-body FDG-PET/CT in patients with a non-FDG-avid pulmonary lesion ≥10 mm that was incidentally found on previous imaging. This retrospective study included a consecutive series of patients who underwent whole-body FDG-PET/CT because of an incidentally found pulmonary lesion ≥10 mm. Seventy patients were included, of whom 23 (32.9 %) had an incidentally found pulmonary lesion that proved to be non-FDG-avid. In 12 of these 23 cases (52.2 %) at least one new incidental finding was discovered on FDG-PET/CT. The total number of new incidental findings was 21, of which 7 turned out to be benign, 1 proved to be malignant (incurable metastasized cancer), and 13 whose nature remained unclear. One patient sustained permanent neurologic impairment of the left leg due to iatrogenic nerve damage during laparotomy for an incidental finding which turned out to be benign. The total costs of all additional investigations due to the detection of new incidental findings amounted to €9903.17, translating to an average of €141.47 per whole-body FDG-PET/CT scan performed for the evaluation of an incidentally found pulmonary lesion. In many patients in whom whole-body FDG-PET/CT was performed to evaluate an incidentally found pulmonary lesion that turned out to be non-FDG-avid and therefore very likely benign, FDG-PET/CT detected new incidental findings in our preliminary study. Whether the detection of these new incidental findings is cost-effective or not, requires further research with larger sample sizes.

Identifiants

pubmed: 38460254
pii: S0899-7071(24)00046-9
doi: 10.1016/j.clinimag.2024.110116
pii:
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D
Radiopharmaceuticals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110116

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Auteurs

Tim E Sluijter (TE)

Medical Imaging Center, Departments of Radiology, Nuclear Medicine, and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: t.e.sluijter@umcg.nl.

Derya Yakar (D)

Medical Imaging Center, Departments of Radiology, Nuclear Medicine, and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Netherlands Cancer Institute, Amsterdam, Department of Radiology, the Netherlands.

Christian Roest (C)

Medical Imaging Center, Departments of Radiology, Nuclear Medicine, and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Charalampos Tsoumpas (C)

Medical Imaging Center, Departments of Radiology, Nuclear Medicine, and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Thomas C Kwee (TC)

Medical Imaging Center, Departments of Radiology, Nuclear Medicine, and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH